$ USD
¥ 人民币
$ USD
€ 欧元
English
简体中文
English
繁体中文
Sign In / Sign up
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Menu
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Home
News
News
Medical Halo Global Pharmaceutical News_Targeted Drugs_New Anti-Cancer Drugs_Overseas Medical Information_【Medical Halo Global Pharmaceutical】
Pemetinib/pemetinib’s prospects for medical insurance and clinical treatment
2026-02-01 22:25:32
Check Details
Domestic purchasing channels and price guide for pemetinib/pemetinib
2026-02-01 22:25:32
Check Details
Pemetinib/Pemetinib is from which company?
2026-02-01 22:25:32
Check Details
Do the latest five targeted drugs for cholangiocarcinoma include pemetinib/pemetinib?
2026-02-01 22:25:32
Check Details
Has anyone used the drug pemetinib/pemetinib?
2026-02-01 22:25:32
Check Details
Is it true that the targeted drug pemetinib/pemetinib will be free for life after paying 100,000 out of pocket?
2026-02-01 22:25:32
Check Details
Can pemetinib/pemetinib be purchased in China?
2026-02-01 22:25:32
Check Details
Is pemetinib/pemetinib developed by the American company Incyte?
2026-02-01 22:25:32
Check Details
New progress in targeted treatment of cholangiocarcinoma: pemetinib/pemetinib and other drugs
2026-02-01 22:25:32
Check Details
Is pemetinib/pemetinib a new hope in the treatment of cholangiocarcinoma?
2026-02-01 22:25:32
Check Details
In-depth analysis: Will pemetinib/pemetinib be free for life after paying RMB 100,000 out of pocket?
2026-02-01 22:25:32
Check Details
Overview of purchasing channels, therapeutic applications and prices of pemetinib/pemetinib in China
2026-02-01 22:25:32
Check Details
1
2
...
547
548
549
550
551
552
553
...
10222
10223
Category
Oncology
Hepatobiliary
dermatology
Endocrinology
Hematology
Andrology
Gynecology
Nephrology
Urology
Department of Infectious Diseases
Gastroenterology
Respiratory department
Neurology
Cardiology and Brain Department
ophthalmology
Psychiatry
Immunology Department
orthopedics
Burn Department
相关知识
1
Lipfendra (Enlicitide): The World's First Oral PCSK9 Inhibitor Approved by FDA
2
Orforglipron: The World's First Oral Small-Molecule GLP-1 Receptor Agonist for Weight Management
3
Cabozantinib Capsules: A Multi-Targeted Therapy for Progressive Medullary Thyroid Cancer
4
Lorlatinib: Mechanism, Advantages, and Key Considerations of Third-Generation ALK Inhibitor Therapy in ALK-Positive NSCLC
5
FDA Approves Subcutaneous Isatuximab (Sarclisa) for Multiple Myeloma: A New Administration Option
6
Pemigatinib Side Effects Explained: Managing Adverse Reactions of FGFR-Targeted Therapy in Cholangiocarcinoma
7
Selpercatinib: Before or After Meals? A Complete Guide to RET-Targeted Therapy Administration
8
Mitotane for Adrenocortical Carcinoma: Dosing Guidelines and Therapeutic Drug Monitoring
9
Vadadustat: Clinical Evidence and Patient Benefits of an Oral HIF-PHI for CKD-Related Anemia
10
Ponatinib vs. Olverembatinib: A Multidimensional Comparison of Third-Generation BCR-ABL Inhibitors
11
Leflunomide and Ocular Adverse Effects: Risk Awareness and Clinical Guidance
12
Clinical Management of Acquired Resistance to Garsorasib (KRAS G12C Inhibitor)